vs

Side-by-side financial comparison of Palomar Holdings, Inc. (PLMR) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Palomar Holdings, Inc. is the larger business by last-quarter revenue ($253.4M vs $151.7M, roughly 1.7× Tarsus Pharmaceuticals, Inc.). On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 62.7%). Palomar Holdings, Inc. produced more free cash flow last quarter ($409.0M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 46.2%).

Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

PLMR vs TARS — Head-to-Head

Bigger by revenue
PLMR
PLMR
1.7× larger
PLMR
$253.4M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+65.7% gap
TARS
128.4%
62.7%
PLMR
More free cash flow
PLMR
PLMR
$396.0M more FCF
PLMR
$409.0M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
46.2%
PLMR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PLMR
PLMR
TARS
TARS
Revenue
$253.4M
$151.7M
Net Profit
$-8.4M
Gross Margin
Operating Margin
28.7%
-5.3%
Net Margin
-5.5%
Revenue YoY
62.7%
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$2.05
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PLMR
PLMR
TARS
TARS
Q4 25
$253.4M
$151.7M
Q3 25
$244.7M
$118.7M
Q2 25
$203.3M
$102.7M
Q1 25
$174.6M
$78.3M
Q4 24
$155.8M
$66.4M
Q3 24
$148.5M
$48.1M
Q2 24
$131.1M
$40.8M
Q1 24
$118.5M
$27.6M
Net Profit
PLMR
PLMR
TARS
TARS
Q4 25
$-8.4M
Q3 25
$51.5M
$-12.6M
Q2 25
$46.5M
$-20.3M
Q1 25
$42.9M
$-25.1M
Q4 24
$-23.1M
Q3 24
$30.5M
$-23.4M
Q2 24
$25.7M
$-33.3M
Q1 24
$26.4M
$-35.7M
Operating Margin
PLMR
PLMR
TARS
TARS
Q4 25
28.7%
-5.3%
Q3 25
27.4%
-12.2%
Q2 25
29.5%
-21.6%
Q1 25
30.8%
-33.5%
Q4 24
28.9%
-36.8%
Q3 24
25.9%
-52.3%
Q2 24
25.5%
-81.6%
Q1 24
29.0%
-136.5%
Net Margin
PLMR
PLMR
TARS
TARS
Q4 25
-5.5%
Q3 25
21.0%
-10.6%
Q2 25
22.9%
-19.8%
Q1 25
24.6%
-32.1%
Q4 24
-34.8%
Q3 24
20.5%
-48.7%
Q2 24
19.6%
-81.6%
Q1 24
22.3%
-129.4%
EPS (diluted)
PLMR
PLMR
TARS
TARS
Q4 25
$2.05
$-0.17
Q3 25
$1.87
$-0.30
Q2 25
$1.68
$-0.48
Q1 25
$1.57
$-0.64
Q4 24
$1.29
$-0.57
Q3 24
$1.15
$-0.61
Q2 24
$1.00
$-0.88
Q1 24
$1.04
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PLMR
PLMR
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$106.9M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$942.7M
$343.4M
Total Assets
$3.1B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PLMR
PLMR
TARS
TARS
Q4 25
$106.9M
$417.3M
Q3 25
$111.7M
$401.8M
Q2 25
$81.3M
$381.1M
Q1 25
$119.3M
$407.9M
Q4 24
$80.4M
$291.4M
Q3 24
$86.5M
$317.0M
Q2 24
$47.8M
$323.6M
Q1 24
$61.4M
$298.5M
Total Debt
PLMR
PLMR
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
PLMR
PLMR
TARS
TARS
Q4 25
$942.7M
$343.4M
Q3 25
$878.1M
$335.1M
Q2 25
$847.2M
$332.6M
Q1 25
$790.4M
$342.5M
Q4 24
$729.0M
$224.5M
Q3 24
$703.3M
$237.5M
Q2 24
$532.6M
$252.2M
Q1 24
$501.7M
$275.2M
Total Assets
PLMR
PLMR
TARS
TARS
Q4 25
$3.1B
$562.2M
Q3 25
$2.9B
$534.6M
Q2 25
$2.8B
$495.0M
Q1 25
$2.4B
$500.8M
Q4 24
$2.3B
$377.0M
Q3 24
$2.3B
$376.3M
Q2 24
$2.0B
$376.8M
Q1 24
$1.9B
$349.3M
Debt / Equity
PLMR
PLMR
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PLMR
PLMR
TARS
TARS
Operating Cash FlowLast quarter
$409.1M
$19.3M
Free Cash FlowOCF − Capex
$409.0M
$13.0M
FCF MarginFCF / Revenue
161.4%
8.6%
Capex IntensityCapex / Revenue
0.1%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$700.6M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PLMR
PLMR
TARS
TARS
Q4 25
$409.1M
$19.3M
Q3 25
$83.6M
$18.3M
Q2 25
$120.9M
$-29.4M
Q1 25
$87.2M
$-20.7M
Q4 24
$261.2M
$-22.2M
Q3 24
$100.3M
$-8.7M
Q2 24
$55.1M
$-14.4M
Q1 24
$33.1M
$-37.8M
Free Cash Flow
PLMR
PLMR
TARS
TARS
Q4 25
$409.0M
$13.0M
Q3 25
$83.6M
$16.3M
Q2 25
$120.8M
$-30.4M
Q1 25
$87.1M
$-21.2M
Q4 24
$260.9M
$-22.3M
Q3 24
$100.1M
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
PLMR
PLMR
TARS
TARS
Q4 25
161.4%
8.6%
Q3 25
34.2%
13.8%
Q2 25
59.4%
-29.6%
Q1 25
49.9%
-27.1%
Q4 24
167.5%
-33.5%
Q3 24
67.4%
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
PLMR
PLMR
TARS
TARS
Q4 25
0.1%
4.2%
Q3 25
0.0%
1.6%
Q2 25
0.0%
1.0%
Q1 25
0.0%
0.8%
Q4 24
0.2%
0.1%
Q3 24
0.1%
0.6%
Q2 24
0.0%
2.5%
Q1 24
0.0%
0.6%
Cash Conversion
PLMR
PLMR
TARS
TARS
Q4 25
Q3 25
1.63×
Q2 25
2.60×
Q1 25
2.03×
Q4 24
Q3 24
3.29×
Q2 24
2.14×
Q1 24
1.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons